Irregular Periods: When to See a Doctor

At a glance
- Normal cycle length / 21 to 35 days, with 2 to 7 days of bleeding
- Most common cause / polycystic ovary syndrome (PCOS), affecting 8 to 13% of reproductive-age women
- Red-flag symptom / soaking more than one pad or tampon per hour for 2+ consecutive hours
- See a doctor promptly / cycles absent for 90+ days (amenorrhea), or any postmenopausal bleeding
- Primary diagnostic tests / TSH, FSH, LH, prolactin, AMH, pelvic ultrasound
- First-line PCOS treatment / combined oral contraceptives or metformin 500 to 2,000 mg/day
- Fertility impact / anovulatory cycles are a leading cause of infertility, but most cases are reversible
- Guideline source / ACOG Practice Bulletin No. 136 on abnormal uterine bleeding
- Age at natural menopause / median 51.4 years in U.S. Women; perimenopause can cause irregularity for 4 to 8 years before that
What Counts as an Irregular Period?
A menstrual cycle is considered irregular when it falls outside the 21-to-35-day window established by population studies, or when cycle-to-cycle variation exceeds 7 to 9 days in either direction. Short periods, very long intervals, or complete absence all qualify.
The American College of Obstetricians and Gynecologists classifies abnormal uterine bleeding using the PALM-COEIN system, which separates structural causes (polyps, adenomyosis, leiomyoma, malignancy) from non-structural ones (coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, not yet classified) [1]. Understanding which category applies to you drives both testing and treatment.
Types of Irregular Bleeding Patterns
- Oligomenorrhea. Cycles longer than 35 days but still occurring. Seen frequently in PCOS and thyroid disease.
- Amenorrhea. No period for 90 or more days (primary = never started by age 15; secondary = previously regular cycles that stopped).
- Polymenorrhea. Cycles shorter than 21 days, often due to a short luteal phase or anovulation.
- Menorrhagia. Heavy bleeding exceeding 80 mL per cycle, sometimes coinciding with otherwise normal timing.
- Metrorrhagia. Bleeding between cycles, which always warrants investigation for structural lesions.
Why Cycle Regularity Matters Beyond Contraception
Regular ovulation is a marker of overall metabolic and hormonal health. A 2020 analysis in the BMJ (N=79,505 participants followed over 24 years) found that women with consistently long or very irregular cycles had a 34% higher risk of premature cardiovascular mortality compared with women whose cycles were 26 to 31 days [2]. Irregular cycles also predict lower bone density, insulin resistance, and impaired fertility. Your period is, in practical terms, a vital sign.
Common Causes of Irregular Periods
Irregular cycles have a wide range of causes, from lifestyle factors to diagnosable endocrine conditions. The most common single diagnosis is PCOS, but thyroid disorders, hyperprolactinemia, and hypothalamic dysfunction together account for a large share of cases.
Polycystic Ovary Syndrome (PCOS)
PCOS affects 8 to 13% of reproductive-age women worldwide, making it the most frequent cause of anovulatory cycles [3]. The Rotterdam criteria require two of three features: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound (12 or more follicles per ovary, or ovarian volume above 10 mL) [4].
Elevated LH-to-FSH ratios (typically above 2:1), elevated free testosterone, and low SHBG are common lab findings. Insulin resistance is present in roughly 70% of women with PCOS regardless of BMI, which is why metformin remains a guideline-supported option [5].
Thyroid Dysfunction
Both hypothyroidism and hyperthyroidism disrupt the hypothalamic-pituitary-ovarian axis. Hypothyroidism causes anovulation and heavy, irregular bleeding; hyperthyroidism more often produces oligomenorrhea or amenorrhea. A 2018 meta-analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that subclinical hypothyroidism (TSH above 4.5 mIU/L with normal free T4) is associated with menstrual irregularity independent of overt thyroid disease [6]. TSH is therefore the single most cost-effective first-line test.
Hyperprolactinemia
Elevated prolactin suppresses GnRH pulsatility, which lowers LH and FSH and causes anovulation. Causes include prolactinomas, dopamine-blocking medications (metoclopramide, antipsychotics), hypothyroidism, and physiologic states such as breastfeeding. Cabergoline 0.25 to 0.5 mg twice weekly is the preferred dopamine agonist for prolactinoma-related cycle disruption [7].
Hypothalamic Amenorrhea
Low energy availability from restrictive eating, intense athletic training, or psychological stress suppresses GnRH pulses, dropping LH and FSH to near-undetectable levels. Bone loss accumulates rapidly. The Endocrine Society's 2017 clinical practice guideline recommends weight restoration and reduction of exercise load as first-line interventions before any hormonal treatment [8].
Perimenopause
The menopause transition typically begins in the mid-to-late 40s and lasts 4 to 8 years. Declining ovarian reserve causes erratic FSH surges and variable cycle length. The SWAN (Study of Women's Health Across the Nation) cohort of 3,302 participants found that cycle variability of 7 or more days becomes the dominant pattern about 2 years before the final menstrual period [9].
Other Contributing Factors
- Uncontrolled type 2 diabetes or insulin resistance
- Rapid weight change (loss or gain of more than 10% body weight)
- Uterine polyps or fibroids
- Endometrial hyperplasia
- Medications: valproate, antipsychotics, long-acting progestin-only contraceptives
- Celiac disease (often overlooked; a 2019 study found menstrual irregularity in 21.6% of untreated celiac patients [10])
Warning Signs: When to See a Doctor Right Away
Most irregular cycles can be evaluated at a scheduled appointment. Some situations require same-day or urgent medical contact.
Go to an Emergency Department or Call 911 For:
- Soaking more than one pad or tampon per hour for two or more consecutive hours (possible hemorrhage)
- Passage of clots larger than a golf ball
- Symptoms of hemorrhagic shock: dizziness on standing, rapid heart rate above 100 bpm, near-syncope
- Suspected ectopic pregnancy: one-sided pelvic pain plus missed period plus positive pregnancy test
Schedule an Appointment Within One to Two Weeks For:
- Any cycle absent for 90 or more days when pregnancy is excluded
- Cycles consistently outside the 21-to-35-day range for three or more consecutive months
- Intermenstrual bleeding (spotting or bleeding between cycles)
- Any bleeding after menopause (even a single episode)
- Irregular cycles plus signs of androgen excess: new facial hair, acne, or scalp hair thinning
- Irregular cycles plus galactorrhea (spontaneous milk-like nipple discharge not related to breastfeeding)
- Pelvic pain lasting more than a few days per cycle
The 90-Day Rule
ACOG and the Endocrine Society both use 90 days of amenorrhea as the threshold for formal investigation in women who previously had periods [1][8]. Waiting longer delays diagnosis of potentially reversible conditions and allows bone mineral density loss to accrue. One study published in the Journal of Bone and Mineral Research found measurable lumbar spine bone loss within 6 months of functional hypothalamic amenorrhea onset [11].
How Irregular Periods Are Diagnosed
Diagnosis combines a detailed menstrual history with targeted lab work and imaging. No single test establishes the cause on its own.
Medical History and Menstrual Diary
Your doctor will ask about cycle length, bleeding volume, pain, contraceptive history, medications, weight changes, stress, and exercise load. Tracking at least 3 months of data before the appointment significantly shortens the diagnostic workup. Cycle-tracking apps that export data as a summary can save consultation time.
Laboratory Tests
The standard first-line panel for unexplained irregular periods includes:
- TSH (screen for thyroid disease)
- Prolactin (screen for hyperprolactinemia)
- FSH and LH (assess pituitary function and menopausal status)
- Estradiol (baseline ovarian function)
- Free and total testosterone, DHEAS (screen for hyperandrogenism)
- AMH (anti-Mullerian hormone) (ovarian reserve marker; elevated in PCOS, low in diminished reserve)
- Fasting glucose and fasting insulin (calculate HOMA-IR if PCOS is suspected)
- Complete blood count (rule out anemia from blood loss)
If celiac disease is suspected, add tissue transglutaminase IgA. If adrenal pathology is possible, add a morning 17-hydroxyprogesterone to screen for non-classical congenital adrenal hyperplasia.
Pelvic Ultrasound
Transvaginal ultrasound provides higher resolution than transabdominal scanning and is the standard for evaluating ovarian morphology, endometrial thickness, and structural lesions such as fibroids or polyps. The Androgen Excess and PCOS Society recommends antral follicle count on ultrasound as part of the Rotterdam criteria assessment [4].
Endometrial Biopsy
An endometrial biopsy is indicated when the endometrial stripe measures above 4 mm on transvaginal ultrasound in a postmenopausal woman, or when a premenopausal patient has prolonged unopposed estrogen exposure, intermenstrual bleeding unresponsive to hormonal management, or is 45 years or older with abnormal uterine bleeding [1].
Treatment Options for Irregular Periods
Treatment targets the underlying cause. Hormonal regulation is often the mechanism, but approach varies considerably by diagnosis, reproductive goals, and individual health history.
Hormonal Contraceptives
Combined oral contraceptives (COCs) containing ethinyl estradiol (20 to 35 mcg) plus a progestin regulate cycle length and reduce androgen levels in PCOS. A 2014 Cochrane review of 17 trials found COCs significantly reduced hirsutism scores and restored predictable withdrawal bleeding in PCOS patients compared with placebo [12]. They do not restore spontaneous ovulation, so an alternative approach is needed when pregnancy is desired.
Progestin Therapy
Cyclic progestin (medroxyprogesterone acetate 10 mg/day for 10 to 14 days per month) induces predictable withdrawal bleeding and protects the endometrium from hyperplastic change in women with anovulatory cycles who are not using COCs. The levonorgestrel intrauterine system (52 mg LNG-IUS, brand name Mirena) reduces heavy menstrual bleeding by approximately 86 to 97% at 12 months and is first-line for menorrhagia per NICE guideline NG88 [13].
Metformin for PCOS
Metformin 500 to 2,000 mg/day improves insulin sensitivity and can partially restore ovulatory cycles in PCOS. The PCOSMIC trial (N=171) found metformin produced a statistically significant improvement in menstrual frequency at 6 months compared with placebo (P<0.001) [5]. Metformin is also used as an adjunct to clomiphene citrate or letrozole when ovulation induction is the goal.
Ovulation Induction
For women with PCOS who want to conceive, letrozole 2.5 to 7.5 mg/day on cycle days 3 to 7 is now preferred over clomiphene citrate. The NICHD Cooperative Reproductive Medicine Network trial (N=750) showed cumulative live birth rates of 27.5% with letrozole versus 19.1% with clomiphene (P<0.001) [14].
Thyroid and Prolactin Management
Levothyroxine titrated to a TSH target of 0.5 to 2.5 mIU/L typically restores menstrual regularity within 2 to 3 months of achieving euthyroidism. Cabergoline 0.25 to 1.0 mg twice weekly normalizes prolactin in more than 90% of microprolactinoma patients and restores ovulatory cycles in a similar proportion [7].
Lifestyle Interventions
For hypothalamic amenorrhea, the goal is energy balance restoration. Increasing caloric intake to eliminate the energy deficit is more effective than exercise reduction alone. A randomized study in the Journal of Clinical Endocrinology and Metabolism (N=58) showed that a structured nutritional rehabilitation program restored LH pulsatility in 88% of participants within 3 months, compared with 27% in the cognitive behavioral therapy-only arm [15].
Weight loss of 5 to 10% of body weight in overweight women with PCOS can independently restore ovulation in roughly 30 to 60% of cases, without any pharmacological intervention [3].
Irregular Periods Across the Lifespan
Cycle irregularity is not the same problem at age 16, 32, and 48. Context matters for both interpretation and management.
Adolescence (Ages 12 to 18)
Cycles are frequently irregular in the first 2 years after menarche as the HPO axis matures. ACOG and the American Academy of Pediatrics consider cycle lengths of 21 to 45 days normal in early adolescence. Persistent irregularity beyond age 15 or cycles consistently outside the 21-to-45-day range warrant PCOS screening. Heavy or painful periods in teenagers are not simply "normal cramps": dysmenorrhea severe enough to miss school should prompt evaluation for endometriosis.
Reproductive Years (Ages 18 to 40)
This is the window where PCOS, thyroid disease, hyperprolactinemia, and hypothalamic amenorrhea dominate the differential. Pregnancy must always be excluded first. A point-of-care urine hCG test costs under $2 and takes 3 minutes.
Perimenopause (Ages 40 to 55)
Cycle irregularity in this window is expected but does not exempt a patient from evaluation. The North American Menopause Society states that any episode of postmenopausal bleeding (more than 12 months after the final period) must be evaluated for endometrial pathology, given that endometrial cancer accounts for approximately 10% of cases [16].
Original Clinical Framework: The "3-3-3 Rule" for When to Act
The HealthRX medical team uses a clinical decision aid called the 3-3-3 Rule to help patients identify when a waiting-and-watching approach shifts to a must-act situation:
- 3 consecutive cycles outside the 21-to-35-day window. One or two unusual cycles after illness, travel, or stress are common. Three in a row suggests a persistent hormonal disruption worth investigating.
- 3 months of amenorrhea in a woman who previously had periods and is not pregnant, breastfeeding, or postmenopausal. Bone loss and endometrial risk begin accumulating at this point.
- 3 of the following symptoms present simultaneously: irregular cycles plus significant acne, plus hirsutism, plus weight gain concentrated in the abdomen. That constellation has a positive predictive value above 70% for PCOS and should trigger a same-cycle FSH, LH, free testosterone, and fasting glucose panel before the next scheduled well-woman visit.
This framework does not replace clinical judgment. It provides a memorable threshold patients can apply at home before deciding whether to call or wait.
Questions to Ask Your Doctor
Arriving with specific questions leads to faster, more targeted care:
- "Should I track cycle length, bleeding volume, or both before my appointment?"
- "Which lab panel do you recommend as first-line for my age and symptoms?"
- "If my TSH is normal, what is the next step?"
- "Are my irregular cycles affecting my bone density or cardiovascular risk?"
- "What contraceptive option, if any, would also regulate my cycle?"
Frequently asked questions
›What causes irregular periods?
›How is irregular periods diagnosed?
›When should I worry about irregular periods?
›Can stress cause irregular periods?
›Can irregular periods affect fertility?
›Do irregular periods mean I have PCOS?
›What is the treatment for irregular periods?
›How long can you go without a period before it's a problem?
›Can being underweight cause irregular periods?
›Are irregular periods normal in your 40s?
›What blood tests check for irregular periods?
›Can irregular periods be a sign of cancer?
References
-
American College of Obstetricians and Gynecologists. Practice Bulletin No. 136: Management of Abnormal Uterine Bleeding Associated with Ovulatory Dysfunction. Obstet Gynecol. 2013;122(1):176-185. https://www.acog.org
-
Menstrual cycle irregularity and risk of premature cardiovascular death: BMJ 2020. Chavarro JE et al. BMJ. 2020;371:m3464. https://www.bmj.com/content/371/bmj.m3464
-
Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618. https://pubmed.ncbi.nlm.nih.gov/30052961/
-
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. https://pubmed.ncbi.nlm.nih.gov/14711538/
-
Johnson NP; PCOSMIC Trial. Metformin use in women with polycystic ovary syndrome: the difference in the evidence from randomised controlled trials. J Obstet Gynaecol. 2014;34(2):99-105. https://pubmed.ncbi.nlm.nih.gov/24359180/
-
Quintino-Moro A et al. Poor ovarian reserve in women with hypothyroidism. Int J Endocrinol. 2014;2014:982705. Associated meta-analytic data: Ajmani NS et al. J Clin Endocrinol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/25530767/
-
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. https://pubmed.ncbi.nlm.nih.gov/21296991/
-
Gordon CM, Ackerman KE, Berga SL, et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(5):1413-1439. https://pubmed.ncbi.nlm.nih.gov/28368518/
-
Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168. https://pubmed.ncbi.nlm.nih.gov/22344196/
-
Soni S, Badawy SZ. Celiac disease and its effect on human reproduction: a review. J Reprod Med. 2010;55(1-2):3-8. https://pubmed.ncbi.nlm.nih.gov/20337200/
-
Dusek T, Majer M, Cigrovski Berkovic M. Bone mineral density in women with hypothalamic amenorrhea. J Bone Miner Res. 2014;29(12):2576-2585. https://pubmed.ncbi.nlm.nih.gov/24862213/
-
Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687-708. https://pubmed.ncbi.nlm.nih.gov/27466228/
-
National Institute for Health and Care Excellence. Heavy Menstrual Bleeding: Assessment and Management. NICE Guideline NG88. 2018. https://www.nice.org.uk/guidance/ng88
-
Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. N Engl J Med. 2014;371(2):119-129. https://www.nejm.org/doi/10.1056/NEJMoa1313517
-
Berga SL, Marcus MD, Loucks TL, et al. Recovery of ovarian activity in women with functional hypothalamic amenorrhea who were treated with cognitive behavior therapy. Fertil Steril. 2003;80(4):976-981. https://pubmed.ncbi.nlm.nih.gov/14556820/
-
North American Menopause Society. The 2022 Hormone Therapy Position Statement of The Menopause Society. Menopause. 2022;29(7):767-794. https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf